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Biopsies of various tissues from eight patients with 
confirmed cutaneous T-cell lymphoma were ana-
lyzed for lymphomatous involvement using V -J junc-
tional sequences in rearranged T-cell receptor-y 
genes as specific molecular markers for the malignant 
clone. The patients included one stage lA, one stage 
m, and six stage IVA. Twenty-five specimens were 
analyzed including 14 skin, five lymph node, four 
blood, and two bone-marrow samples. Ten skin sam-
ples and four lymph node samples were histologically 
positive for lymphOlna. The other specimens were 
morphologically uninvolved. An assay involving 
polymerase chain reaction (PCR) amplification of 
T-cell receptor-y gene rearrangelnents and denatur-
ing gradient gel electrophoresis was used to identify 
the tissue specimen containing the greatest tumor 
clone density in each case. This specimen was then 
used to generate a tumor-specific RNA probe that 
was used to molecularly stage each patient by means 
Lymphoid m alignancies can be detec ted as a clonal excess of a specific antigen receptor gene rearrange-men t over polyclonal rearrangements by analysis of genom ic DNA extracted fi'om biopsy specimens w ith the Southern blot technique [1-7]. Although a South-
ern bl o t is labor intensive and requires DNA from at least 106 cells 
for on e assay, the recent in troduction of amplification of rearranged 
antigen receptor genes by the polymerase chain reaction (PCR) 
allows analysis of ex tremely small samples [2]. Previo usly, we 
described the rapid de tec ti on of clona l T -cell receptor), chain 
(TCR-),) gene rea rrangements by the combination of PC R and 
denaturing g radi ent gel electrophoresis (PCR /DGGE) as a diag-
n ostic crite rio n for lymphoid neopl asms [8,9]. In addition, we have 
developed a PCR-based RNase protection assay (PC R /RPA) for 
the specific detectio n of the individual malignant clone in acute 
lymphoblastic leukemia by its TCR-), gene rearrangement [10]. 
T his assay is ab le to detect a single malign ant ce ll am ong 105 normal 
bone marro w ceUs. 
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of an assay involving PCR gene amplification and 
RNase protection analysis (pCRlRPA). This assay 
detected malignant cells in all available biopsies, 
including morphologically uninvolved extracutane-
ous tissue samples (two blood, one lymph node, and 
one bone marrow) obtained from the two patients in 
pathologic stage I. Microscopic examination and the 
less sensitive PCR/denaturing gradient gel electro-
phoresis technique failed to detect lymphomatous 
involvement in 11 (44%) and eight (32%) of these 25 
specimens, respectively. We conclude that molecular 
biologic staging using PCR/RPA is able to demon-
strate morphologically occult dissemination of cuta-
neous T-cell lymphona in early disease. In addition, 
PCRJRPA may be able to monitor tumor response to 
therapy and detect early recurrence of malignant 
lymphomas during clinical remission. Key lVords: poly-
merase chaitl reactioll/RNase protectioll.lT-cell receptol' gelle 
rearratlgeltlellts. ] Invest Dem,atoI104:889-894, 1995 
In this study, we have tested the hypothesis that the detection of 
malignant lymphocytes with molecular assays of high sensitivity 
might be a significan t improvement fo r the staging of a solid 
lymphoid malignan cy. We decided to focus on the an alysis of 
cutaneous T-cell lymphoma (CTCL) for several reasons . First, the 
stage of CTCL at the tim e of diagnosis clearly has prognostic 
signifi can ce for both the response to therapy and surVival of the 
patients [11] . In addition, the analysis ofTCR gene rearrangements 
is a w ell established procedure for this type of malign an t lymphoma 
[1 2,13 ]. T hird, skin biopsies with a scant lymphoid in fi ltrate are 
o ften seen in this disease a.nd frequently do not yield sufticient DNA 
for Southern blot ana lys is [9,1 1] . Finally, we had access to a well 
charac terized group of patients with CTCL w hose diagnostic 
biopsies had already been analyzed for clonal TCR-), gene rear-
rangements by PCR/DGGE. W e n ow describe the molecular 
de tec tion of lymphomatous involvement in a var.iety of cutaneous 
and extra cutaneous biopsy specimens from these patients and 
compare the lise of the afo rementioned assays with conventional 
diagnostic methods. 
MATEIUALS AND METHODS 
Case Selec tion Eight patients fro m a previous study investigating the use 
of PCR/ DGGE in the diagnosis of CTCL 19] had at least two different 
biops ies \-vith rC1naining froze n 111 atcri:t1 an d \:vere chosen fo r this study. A ll 
patients h"d histologicall y confirmed disease and clona l TCR-y gene 
rea rrangemcnts as shown by PCR/ DGGE. Table I sllmmarizes the diag-
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Table I. Detection of Involvement by CTCL Using Histopathology, PCRJDGGE, and PCRJRPA Shows an Increasing 
Hierarchy of Sensitivity" 
Patient 
(Stage) 
Biopsy 
(Date) 
Histopathology 
(Sensitivity, 56%) 
PC R./ DGGE 
(Sensitivity , 68'10,) 
PCR./ R.PA 
(Scnsitivity, 100%) 
A (IV A) 
(T3N3MOBO) 
MF 
MF 
MF 
MF 
MF 
+ 
+ 
+ 
+ 
B (IV A) 
(T3N3MOBO) 
C (IV A) 
(T2N3MOBO) 
Skin tumor (12/ 14/89) 
Skin patch (12114/89) 
Lymph node (12114/89) 
Skin tumor (1/10/91) 
Lymph node (1110 /91) 
Skin patch 1 (2121/90) 
Skin patch 2 (2/21/ 90) 
Lymph node (11 /26/90) 
Blood (3 /20/90) 
C hronic dermatiti s 
Chronic dermatiti s 
M F + 
Pro be 
1:500 
1:500 
Probe 
1 :100 
1 :200 
1 :500 
Probe 
1 :500 
Probe 
N ormal 
MF 
MF 
MF 
D (IV A) 
(T2N3 M0131 ) 
E (IV A) 
(T4N3MOBO) 
Skin plaquc (4 /25/90) 
Skin patch (4/25/90) 
Skin plaque 1 (9/5/90) 
Skin plaque 2 (1/2191) 
Skin papules (11 /28/90) 
Bone marrow (9 / 17/90) 
Blood (10 /3/90) 
C hronic dermatiti s 
(post R.:x) 
Chronic dermatiti s 
(post R.x) 
Normal 
Norma l 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ (VI'I) /+ (V y9) 
- (Vyl) /+ (Vy9) 
+ 
1 :5 
Probe 
1:'10 
1:10 
1 :10 
1 :10 
Probe F (IV A) 
(T3N3MO BO) 
G (IA) 
(TINOMOBO) 
Skin tumor (1/14/91) 
Lymph node (1/18/91) 
Skin patch 1 (214/91 ) 
Skin patch 2 (2 /4/9 1) 
Lymph node (2/4/91) 
Bone marrow (7/30/90) 
Blood (6/5/91) 
MF 
MF 
MF 
MF 
Normal 
N ormal 
Non11al 
1 :5000(Vyl) / 1:1 0(Vy9) 
+ 
H (m) 
(T2NOMOBO) 
Skin patch (6 / 19/91) 
13Iood (6 /20/ 91) 
MF 
N orma l (rolrc 
atyp ica l cell s) 
+ 
1 :5 
Probe 
1 :200 
1 :1 00 
1:100 
Probe 
1:500 
" MF. mycosis fungo idcs; lu. Radiation therapy. + denotes clona l pattern all DGGE; - denott.!s pol y..:onal smear 0 11 D GGE. Patient F wa s an"l yzcd usin g cl onal Vrl and V)'9 
rearrangements (sec text). The results of th e l"tNasc protection assays nrc given ;IS the relati ve illten sity of the tumor-specifi c bands comp<1rcd to logaritlltllic diJutlOI1S or DNA from 
the respective diagnosti c bio psy into no rmal PBM C DNA. Stag ing h;) scd 011 critcri:l re viewed ill 111l 
nos is and pathologic stagc at thc time w hen the bi opsies werc performed, 
the type of tissuc biopsicd, and thc date of thc procedurc. All paticnts werc 
diagnosed with mycosis fun goidcs (MF), a subtype of CTCL that typ ica ll y 
presents onl y with skin lesions [11 j. Thc diagnos is of CTCL was cstablished 
according to routinc clinica l and hi stopathologic criteri a [11] . The de finition 
of pathologic stages was taken from [11]. Bccause biopsies were generall y 
performed onl y when extracutaneous diseasc was suspected clinicall y, the 
majority of patients te nded to be in stage IV . However, no paticnt had 
cxtracutaneous manifestation of the discase by hi stopatho logic criteria apart 
fro m invo lvement of lymph nodcs in six paticnts and peripheral b lood in 
o ne patient. 
Samples All biopsies were perfo rmed with informcd consent. A part of 
each specimen was proccssed for histopatho logic examination . The rcmain-
ing material was cryoprcsc rved at - 70°C un ti l furth er processing. Normal 
pcripheral blood was obtai ned from hea lthy vo lunteers. Mononuclea r cell s 
from blood and bon e-marrow spccimens were purificd by Ficoll density 
gradicnt centrifugation. DNA was extracted fro m ti ss ucs using routine 
procedures [1 4]. 
PCR/DGGE T he o ligonucleotide primcrs used fo r PC R / DGGE were 
designcd to ampli fy TCR-y genc rca rrangements invo lving Vy l-9 and 
J y 1-2 genc segments i.l 5-1 8] . R earranged TCI~-y gellcs were amplified 
fi-om 1 p.g of DNA using downstream primcr J yl. 2 (CGTCGACAA-
C AAGTGTTGTTCCAC) and ups tream primcrs Vyl .2 (GAA GCT-
TCTAGCTTTCCTGTCTC) o r Vy9 .1 (GGA ATTCC AAATTC TTG-
GTTTA) as describcd previously 191. Briefly, thc first roulld consi sted of25 
cycles each of which included DNA dcnaturation at 94°C fo r 1 min (3 min 
in the first cycle), primcr an nea ling at 55°C fo r 1 min, and primer extcnsion 
at 70°C for 1 min (6 min in the last cyclc). Twenty pcrcent of thi s reaction 
product was rcampLificd with nested downstream plimer J yi nt (GGATC-
CACTGCCAAAGAGTTTCTT) and ncsted upstream primer Vyint (CT C-
GAGTGCGCTGCCTACAGAGAGG) or Vy9. 1 fo r 15 cycles under simil ar 
conditions. If insufficient product was present aftc r the sccond round of 
PC R, the second round was performed for 25 cycles. All PCR products 
were ana lyzed by gel electrophorcsis thro ugh 1.2% agarose to demonstratc 
succcssfu l <lmp li fi cation and homogcncity of the product. To check for 
possiblc contamina tion by spurio us DNA tcmplatcs, rcactions without 
add ition of DNA wcre I e rfo rmcd with c;lch cxpcrill1cnt . T hese control 
reactions consistently f.1 il ed to show an)' product detectable by agarose gel 
c lectrophorcsis. PC R prod ucts werc precipitatcd with ethanol and 50% of 
e<leh prepa ration was analyzcd by DGGE as de~cribed [8 ,9J. Briefly, samples 
were dcnatured at 95°C and reannc<lled at 60°C. Electrophoresis was 
pcrfoJ'med at 60°C for 6 h at 150 V th rough 6.5% polyacrylamide containing 
an inc reasing linear gradien t from 2.45 M ure<l / t4 ')/u formamid e to 3.85 M 
urea/22% formamid c. Gels werc stained with ethidium bromide and 
photographed under UV transillumination. 
PCR/RPA An ~asc protection assay for the detcction of specific clonal 
T Il..-y rearrangcmcnts was performed as described and illustrated previ-
ous ly 110]. Driefly , a tumor-specific RNA probe was generated by PCR 
amplification of DNA from specimens hi stopatho logica lly diagnosti c for 
CTCL and showing the strongest clonal band patte rn by PC R / DGGE 
ana lysis. This was accomplished using downstream primcr JyT7 (GCTA-
ATACGACT C ACTATGGGAGAGA AA CAAGTGTTGTTCCAC) and 
Upstream primers Vyl.3 (CGGCTA C ATCCACTGGTACCT) or Vy9.4 
(CGCCTGGAATGTGTGGTGTCT) . The sequence of the promoter ofT7 
RNA po lymcrase is underlined [1 9]. Amplifications were carried out in a 
volume of 50 p.1 for 30 cycles w ith an annea ling tcmperature of 60°C. Other 
PC R condi tions were similar to those noted above for PCR/ DGGE. Ten 
perce nt of this PC R. product was transcribed ill lIifm using a transcription kit 
(Stracagenc , La J o ll a, CAl with lOU ofT7 ~A po lymerase and 2 mCi / 1111 
of a_32p_UTP (800 C i/ ml11oi; Dupont, NEN , Boston, MA) in the presence 
of unlabcled ATP, CTP, and GTP according to the instructions of the 
manufacture r. Test RNA was similarl y syn th esized by PCR ampli.fi cation 
using down-stream primer J y l7 (GTTCCACTGCCAAAGAGTTTCTT) 
'lI1d llpstream primcrs VyT7 (GCTAATACGACTCACTATGGGAGACG-
GCTACATCCACTGGTACCT) or Vy9T7 (GCTAATACGACTCACTAT 
GGGAGACGCCTGGAATGTGTGGTGTCT) under otherwise identical 
condi tions, and subsequent transcription of 20% of thi s product with 20 U 
T7 RNA polymerase in the presence of unlabe led NTPs. After transcrip-
tion , the DNA templatc was digested with 40 U RNase-frce D Nase I 
(Bochringer Mannheil11 , Gcrmany) . Two to fivc perccnt of the I~A pro be 
was hy bridized to 20% of each tcst RNA ovemight at 64 °C in 85% fonnamide l 
1 111M ethylcnediaminetetraacetic acid / 40 111M piperazine N-N ' - bis:2-
e thane sulfonic ac id (PIPES; pH 5.6). The resul ting RNA hybrids wcrc 
subjected to digestion with 40 p.g/ml I~ase A (Boehringer Mannheim) at 
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40 -42°C for 30 min, precipitated with ethanol , and analyzed for 2 h at 45 
V Icm by gel electrophoresis through 6'Y" polyacrylamide/7.6 M urea. Gels 
were exposed to XAR. 5 tilm (Kodak. R.ochester, NY) overnight at - 70°C 
'\>vith an intensifying sc reen. Visual inspection "vas used to pcrfornl senli-
quantita tive assessment of PCR./ R.PA band intensities in serial dilutions of 
diagnostic test R.NA into norm;ll blood control DN A. 
RESULTS 
Detection of Dominant Clonality Using PCRJDGGE In a 
first step toward molecular staging of the disease, PCR/ DGGE was 
p e rformed with DNA extracted from every biopsy of each CTCL 
patient. As denaturing gradient gels separate DNA fra gm ents based 
011 th eir precise nucleotide seque nce in addition to their size [20], 
PCR products of TCR-'Y gene rearrangements present in a poly-
clonal population of cell s form a smear over the length of the gel, 
w hereas a clonal fraction of at least 0 .1-1% of cells with a 
rearranged TCR-'Y gene results in one or more distinct bands [8,9]. 
C lonal bands were considered val id when the same patte rn of bands 
was detected e ithe r in more than one biopsy specimen from the 
sa m e pati ent or in at least two independent PCR amplifi cations of 
DNA from th e same site. Table I shows the results ofPCR/DGGE 
analysis in comparison to the histopatholog ic eva lu ation. In. six 
patients, detection of c10nality by PC R / DGGE correlated with the 
result of microscopic exa mination. However, PCR/ D GGE clearly 
demonstrated the presence of the same clonal population of cells in 
fOlll' diffe rent biopsy specimens fi'om patient E that were deemed 
uninvo lved by morphologic criteria. In contrast, PCR/OG GE 
failed to demonstrate unequivocally lymphomatous involvem ent of 
a lymph node that histologically was considered positive for t he 
presence of the tumor (patient A) as w e ll as in several other tissue 
samples that were histologica lly uninvolved by CTCL. 
Generation of Tumor-Specific RNA Probes In the next se t 
of ana lyses, a tumor-specific, radiolabelcd RNA probe was gen e r-
ated for each case. DNA from the bio psy showing the strongest 
clonal band by PCR/DGGE was amp lified with the primers J 'YT7 
and V'Y1 .3, fo llowed by ill lI ifro transcription in the presencc of 
32 P_labe led UTP. T he most inten se clonal bands de tected by 
PCR/ DGGE w e re found in skin lesions in seven of the e ight 
patie nts. Only thc tumor-specifi c RNA probe of patient C was 
synthesized fi'om a lymph node biopsy, beca use using histology and 
PCR / DGGE, the skin lesions of this patient appeared to b e in 
remission at the tim e of the biopsy after e lectron bea m radiation 
th erapy. 
Molecular Staging Using PCRJRPA The tumor-specific 
RNA probe of each patient was hybridized to test RNA gen et<lted 
from each of the other ava ilabl e biopsies fi:om that patient and from 
logarithmic dilutions of DNA extracted from the diagnosti c site 
into normal pe ripheral blood DNA obtained from h ea lthy volun-
teers . After hybridiza tion, the resulting RNA duplexes were sub-
j ected to diges tion with RNase A, followed by polyacrylamide gel 
electrophores is unde r denaturing conditions and au toradiography. 
Test RNA synthesized fi'om peripheral blood of fo ur normal 
individuals was analyzed in parallel in each assay to exclude 
fa lse-positive results. In prior studies using PC R / RPA, fa lse posi-
tives w e re also excluded usin g normal bone-marrow controls [10]. 
As shown in Table I, PCRI RPA detected the respective tUl11or-
specific TCR-'Y gene rearrangement in every available biopsy 
specimen fi'om each of the patients in this series. T hese results 
indicate a widespread dissemination of the disease not only in 
patients with known extrac utaneous Icsions, but possibl y also in a 
substantial number of patients in stage I at the time of diagnosis. 
Patient H, w ho was in stage I, had a few morphologically 
abnormal cells in his pcriphe ral blood without fu lfilling the C1'iteria 
for blood involvement [11] . PCR / OGGE fa il ed to demonstrate a 
clonal pattern un equivocally. PC R / RPA , however, clearly re-
vealed circula ting cell s o f the m alignant clone. Figure 1 shows the 
.ma lysis of biopsies from patient G who was also in stage r. An 
aliquot of the RNA probe of this case that has not been subjected 
to digestion with RNase A has a clonal band length of appl'oxi-
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Figure 1. PCRfRPA demonst.rates systemic involvement by CTCL 
in stage I disease. RNase protection assay of DNA extracted from biopsies 
of patient G and normal peripheral blood mononuclear cells using an RNA 
probe derived from a diagnostic skin biopsy specimen. For quantitation of 
the involvement of the nondiagnostic biopsies, logarithmic dilutions of 
DNA from the diagnostic biopsy into nomlal PBMC DNA were analyzed in 
parallel. T he position of the tumor-specific protected band is indicated by 
the a rro fII. The size markers are 35S-labeled Hi,t}I / EwRl restriction frag-
ments of the plasmid pBR.322. 
mate ly 251 base pairs (lane 16). Also presen t in this lane is a sm ear 
that presumably stems from reactive lymph ocytes found in the 
les iona l tissu e. As the test RNA transcribed from a PCR product 
amplified with primers Vyr7 and J'YI7 is shorter than the RNA 
probe, probe mol ecules that have been protec ted from RNase 
cleavage by perfectly matched tes t RNA gen erated from DNA of 
cells of the CTCL clone have a length of232 base pairs [10]. Apart 
fi'om th e diagnostic sample in lan e 1, a band is detectable in this 
position in lanes 7-10, indicating the presen ce of the tumor in a 
second skin biopsy, peripheral blood, bone marrow, and a lymph 
nod e, although the patient was clinically and patholog ically in stage 
lA . The same band is also present in a dilution ofl0 - 2 of the DNA 
from the diagnostic spccime n into no rmal pe ripheral blood DNA. 
T hi s limiting diluti on step appears consid erabl y lowet· than the 
sensitivity of 10 - 5 that has been reported for PCR/ RPA in the 
analysis of acute lymphoblastic le ukemia [10]. T h e m ost likely 
explanation for the diffe rence is that, in contrast to diagnostic 
bonc-marrow aspirates of acute leukemias , the m alignant cell clone 
ti-equently comprises only a minor fraction of ti,e total cell popu-
lation in a typical lesion ofCTCL [21] . T his is due to an often large 
number of reactive lymphocytes and the in variable presen ce of 
keratinocytes, fibrobl asts, and other stromal cells in ski n biopsies . 
Consequently, the tumor-specific gene rearrangem ent m ay be 
diluted out eadi er than it would have been using a relatively 
homogeneous tumor cell population . 
Findings Suggestive ofOligoclonality in Some CTCL Cases 
A discrepancy between the m o lecu\;lr assays and light microscopy 
was noted in patien t F. Although lymphomato us in volvement of a 
lymph node was diagnosed histologically, PCR/ P..PA performed 
using the clonal V'YT-rearrangement demonstrated a tumor-specifi c 
band o nly at the low intensity of 1 :5000, whereas PCR/ DGGE did 
not detect a clonal band. T his finding is in con trast to the analyses 
of other patients, where the m aximum sensitiv ity of morphologic 
examination was found to correspond to a lim iting dilution in 
PC R / RPA of 1 :500 (patient A) or hig her. Therefore, we decided to 
study the clo nal TCR-'Y gene rearrangem ent containin g thc Vy9 
genc segm ent that had been found in the diagnostic skin specimen 
of this patient [9]. Surprisingly, PC R / DGGE readily detected ti,e 
same clonal V 1'9 rearrangement in both the skin and lymph node 
biopsies (Fig 2) . PC R / RPA perfo n1l ed with the primer set for V'Y9 
rearrangem en ts showed a strong tumor-specific band with only 
slightly d iminished intensi ty whcn compared to the diagnostic 
sample (Fig 3). 
Two explanations can be o fFered for this finding. First, as the 
normal polyclona l rearraJlgem ents compete with the tumor-specifi c 
rearrangements during the PC R. reactio n, a clonal Vy9 rearrange-
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Figure 2. PCRlDGGE detect s clonal T-cell populations in diagnos-
tic skin and lymph node biopsy specimens from CTCL patient F. 
DNA extracted from both biopsies was ampli fied with the primer pairs 
specific for V yl and V y9 TCR-y gene rearrangements. T he clonal control 
lanes arc DNA from the Iymphoblastoid ce ll li ne SUP-B7 for VyI and an 
amplified Vy9 TCR-y gene rearrangement cloned into the phage 
M13mp18 (GrJa1.2) . The polyclonal control lanes contain DNA from 
normal PBMC for both primer combinations. 
ment may be amplified better than a clonal Vyi rearrangement and 
ultimately give a stronger signal because rearrangements involving 
the Vy9 gene segmen t are generaUy less frequent than rea rrange-
ments involving the nine members of the Vyl subgro up . Second, 
the tumor of thjs patient may consist of two m aljgnant clones of 
lymphocytes , each distinguished by a different type ofTCR-y gene 
rearrangement. Although both clones may be equally represented 
in the skin b iopsy, the clone carrying the rearrangement utilizing 
Vy9 cou ld h ave spread preferentiaUy to the biopsied lymph node. 
The tumor of patient D represents anoth er example of CTCL 
with two possible clonal celJ populations. C lonality was detected in 
the diagnostic lesion for Vyl and Vy9 by PCRlDGGE [9]. When 
the PCR primers for Vyl were used to generate the RNA probe for 
RPA analysis, the undigested probe clearly consisted of two 
separate bands of approxll1ately eq ual intensity (not shown) . These 
findings indicate the presence of two di stinct V y l TCR-y gene 
rearrangements and at least one rearran gement involving the Vy9 
segment in tlus tumor. 
DISCUSSION 
Tlus study demonstrates the use of a sensitive and tumor-specifi c 
molecu lar staging procedure for CTCL. A combination of PCR 
V~ 
V'y9 
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Figure 3. PCRlRPA detects clonal T -cell populations in diagnostic 
skin and lymph node biopsy specimens from CTCL patient F. DNA 
extracted from both biopsy specimens of patient F and normal PBMC was 
ana lyzed using RN A probes deri ved from the clonal V yl and V y9 rear-
rangements of the diagnostic skin specimen of patient F. For quantitation of 
the involvement of the lymph node biopsy, logari thmic dilutions of DNA 
frO I11 the diagnostic skin biopsy into normal PBMC DNA were ana lyzed in 
parallel. The position of the respective tumor-specific protected band is 
indicated by the a,.rows. 
amplification of rearranged TCR-y genes and RNase protection 
assay was found to be considerably m ore sensitive than lustopatho-
logic exammation for detenninin g the extent of the disease. T he 
malign ant T-cell clone could be detected by PCR/RPA in all 
available biopsy specimens from six patients beyond stage l. T h ese 
data support the concept ofCTCL as a systemic disease and suggest 
that any potentially curative therapy in advanced-stage CTCL 
wou ld have to be based on a systemic approach . 
In addition, malignant cells were aJso found in extracutaneous 
specimen s of two patients considered to be in stage l. T his finding 
is of special interest because good control of disease, som etim es 
including complete remissions of long duration , can be aclu eved ill 
the m ajol;ty of tlus group of patients by a variety of treatment 
optio ns targeted at the skin. T hese therapies include topical 
mechlorethamine, electron beam radiotherapy, or combined ad-
ministra tion of psora len and irradiatio n w ith UV A ligh t (PUV A) 
[11 ,22,23]. Further studies are indicated to determine whether the 
detection of extracutaneous disease with highly sensitive diagnostic 
techniques at tlus stage corre lates with the clinical response to 
therapy . However, prognosis in CTCL is related to con vention al 
clinicopatho logic staging [11] . It h as not yet been established 
whether the de tection of the tumor clone in histologica ll y unin-
volved extracutaneous tissues h as any prognostic relevance in this 
disease. N everth eless, molecular stagin g couJd potentiall y help to 
define prognostic subgro ups m o re accurately than prev io usly pos-
sible. 
Apart from detecting lymphomatous involvem ent in histopatho-
logically n orma l tissues, o ur data also show that PCR/RPA has 
superior sensi tivity when compared to PCR/DGGE. H owever, thjs 
fact does not dimitush the usefuln ess of PCR /DGGE b ecause each 
test has been designed to address somewhat different diagnostic 
problems. T he m ajor application ofPCR /DGGE is likely to be th e 
primary diagnosis of malignan cy based on the demonstration of 
clonality among lymphocytes, particularly w hen a relativ ely small 
number o fl ymphocytes is ava ilab le for an alysis [9]. In contrast, th e 
PCR./RPA tecluuque was developed as a staging tool to detect the 
dissemination or persisten ce of a parti cular malignant lymphoid 
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clone with extreme sensitivity in patien ts w ith a proved lymphoid 
malignancy [10]. In fact, PCR/RPA requircs a diagnosti c refere nce 
tissue for construction of probes used in the procedure. In the 
curren t study, the selcction of tlus refe rcnce tissue was based on 
PCR./DGGE resu lts. T herefore, both techniques complement each 
other for different steps in the diagnosis and staging of a lymphoma 
rather than represent alternativc approaches for the samc problem. 
Extensive studies involving a variety of inflammatory skin disease 
controls wi ll be required before it can be determined w hether 
PCR/ RPA can be used reliably to identifY occult neoplastic T-cell 
clones in cases of CTCL that are so early that thcy fa il to show 
dominant clonality by PCR/ DGGE. 
Prior reports have described the tumor-specific detection of 
circulating malignant cell s in Sezary syndrome, a systemic subtype 
of CTCL characterized by generalized erythroderma and large 
numbers of atypical lymphocytes in the peripheral blood [11] . 
T hese approaches relied on PCR amplification of the TCR.-i3 chain 
gene rearrangement of the individual tumors [24,25] . As a neo-
plasm of the mature T -cell type, virtuaUy all cases of CTCL can be 
expected to carry and express a rearranged TCR-i3 gene [11 ,12]. 
Howeve r, the TCR-i3 locus comprises at Icast 24 Vi3 subgroups [4] . 
This complexity makcs the choice of o ligonuclcotidc primers for a 
successfu l PCR amplifi ca tion of TCR-i3 gene realTangemcnts 
difficult and necessitates the use of RNA as the starting mate rial. 
PCR amplification of TCR-i3 gene rearrangements has becn 
accomplished by the use of a panel of prime rs specific fo r each V i3 
gene family [26]. To avoid performing multiple amplification 
reactions with a panel of V i3-specific primers, one group has 
described the use of a sin gle, highly degencrate primcr in conjunc-
tion with a Ci3-primer to amplify rearrangements involving 18 V i3 
gene £:'.I11ilies [24]. Under thcsc conditions, however, the PCR 
product appears to be rather impure and to contain a variety of 
nonhomologous fragments [24]. The other report involved the use 
of a specifica Uy designed 111ultiprobc RNase protection assay as an 
additional preliminary ana lytic step to identify the correct Vi3 fami ly 
prior to PCR amplification [25]. In both of these approaches, the 
precise base composition of the V -D-J junction of the clonotypic 
rearrangement is determined by cloning of the PCR product and 
DNA sequencing. Tn the next step, an o ligonucleotide probe 
specific for the junctional region is chemica Uy syn thesized to 
filcilitate detection of tumor ceUs by subsequent PCR amplification. 
Both approaches werc able to demonstratc circulating tumor cclls 
ill Sezary syndrome. T he former method has also been used to 
d!'! tect tumor cells in histologically uninvolv ed skin and lymph node 
but not blood o btained from one patient w ith mycosis fungoidcs 
[Lcssin SR, D iLosa RM, Bcnoit B, Jaworsky C, Rovera G: 
Molecular detection of malignant infiltration in uninvolved skin 
and lymph node in a patient with cutaneous T -ccll lymphoma 
(CTCL) (abstr).) It/lles/ Der/lla/of 96:535. 1991]. 
In contrast to thesc methods, the molecular assays uscd in tlus 
report assess TCR-y rather than TCR-i3 gene rea rrangements. 
Although the TCR-y gene is rarely exprcssed, it nevertheless has 
undergone rearrangement in the overw hclming majority of CTCL 
cases [9,27]. We chose to study TCR-y gcne rearrangemcnts as 
diagnostic markers for these tumors because the comparatively 
simple structurc of this locus makes it particularly suitable for 
PCR-based analyses L4,5]. Both the PCR./DGGE and PCRJ RPA 
techniques are routincly performed with o l1ly two scts of PCR 
primers. T hese primer combinations permit the analysis of TCR-y 
gene rearrangcmcnts involving most of the Vy gene segments 
known to undergo genetic recombination [16-18] . From O ul' 
experience. over 90'X, of aLI TCR-y gene rearrange men ts are 
amplifi ablc with this approach [9]. R.are rcarrangements involving 
the remaining Vy genes can bc amplifi ed using two additional 
Vy-specifi c PCR primcrs (unpublished results). Apart fi'0111 the 
simplicity of the PCR amplification , PCR/ IU'A has the additiona l 
important advantage that cloning of the peR products, DNA 
sequencing and chem ica l o ligonuclcotide synthesis arc not required 
for each individual casc. Moreovel', the initial substrate for analysis 
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is DNA rather than RNA. RNA is less stable and may be less 
reliably isolated from biopsy specimens. 
T lus study demonstrates the applicability of the PCR/RPA 
tcchnique even in situations whcre a significant proportion of thc 
so-ca lled tumor- specific RNA probe consists of polyclonal se-
quences derivcd from reactive T lymphocytes present in the 
diagnostic lesion. Although impuri ty of the probe undoubtedly 
affects the sensitivity of thc technique, earlier studies show that 
non-homogeneity of thc probe does not reduce the sensitivity of 
PCR/ RPA as much as may be anticipated. For example, a clona.l 
population represenbJlg only 0.1% of the total cell s in bone marrow 
cou ld sti iJ bc used to generate a probe that detected a 1:1000 
dilution of DNA fi.'om that clone in DNA from polyclonal cells 
[10]. Tt may be possiblc to enhance the scnsitivity of the teclmiquc 
by amp lifYing the probe from DNA ofTCR-y gene rearrangements 
purified fi'om the diagnostic specimcn. Tlus could be accomplished 
fairly easily by extracting thc clonal bands fi'om DGGE gels . In any 
event, as suggested by our data in dlis report, maximal sensitivi ty of 
the technique may not bc necessary to find disseminatcd CTCL in 
most cases. 
[n our study, CTCL was used as a model disease for the sensitivc 
molecular staging of m alignant lymphomas. The results demon-
stratc that PCR/ RPA is readily applicable for lymphomas canying 
TCR-y gene rearrangements. FUI'ther'J11ore, PCR/ RPA can be 
modified for analysis of rea rrangements of the immunoglobulin 
heavy chain gene (unpublished results). This application is likely to 
cxtend thc use of this assay to most lymphomas of B cell lineage, 
which comprise the majority of all lymphoid neopla sms [1]. As in 
CTCL, a sensitive molecular-staging procedurc such as PCR/RPA 
cou ld potentia.lly improve the definition of prognostic subgroups in 
other Iymphoproliferative processes. Furthcrmore. the availability 
of more accurate staging could eventually improvc the selection of 
appropriate treatment for patients with potentially curable condi-
tions such as large-ce ll lymphoma. PCR-based assays might also 
allow a more accurate monitoring of individual lymphom a patients 
during remission to identifY patients who might benefit from 
additional therapy. Finally, these assays could be usefu l in treatment 
regimens involving transplanting with auto logous bone marrow or 
peripheral bone-marrow stcm cells by permitbJlg screening of grafts 
for occult malignancy. 
T"is ",ork "'ns sll)J)JOI1ed 1>)' gmlll POI CAJ<: 183 jimll II, r Nnliollfll 111Slilllles of 
H enll" mid n rOlllmel ji'DIII I"e Nn liClllnl FOI llldnlioll ji'" C nllrer R esenrr" (Dr. Skim) 
nlld 1>)' N TH gmllls A R40844, A R 39750, nlld CA600'/4 nlld Merit R eIJiclI' 
jillldillc~ jimll I"e Oepnrllllelll of lIelern lls Ajj'nirs (Dr. Wood). I,Ve /"nllk R nrlwl 
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